EUCTR2011-002941-36-NL进行中（未招募）不适用
Multicenter phase 1/2a study using T-cell receptor gene therapy in metastatic melanoma - TCR trial
KI-AV0 个研究点目标入组 25 人开始时间: 2012年4月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must be = 18 years of age.
- •Patients must have measurable metastatic melanoma
- •Patients must be HLA-A2 positive.
- •Patients must have a clinical performance status of ECOG 0 or 1.
- •Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for four months after receiving the preparative regimen.
- •Patients must be able to understand and sign the Informed Consent document.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •Life expectancy of less than three months.
- •Patients with metastatic ocular or mucosal melanoma.
- •Requirement for systemic steroid therapy.
- •Patients who have a history of more than two CNS metastases.
研究者
相似试验
已完成
2 期
Multicenter phase I/IIa study using T-cell receptor gene therapy in metastatic melanomamaligne melanomauveal melanoma1003005410040900skin cancerNL-OMON47165ederlands Kanker Instituut20
招募中
不适用
This is a multicentric study in which metastatic melanoma patients that have already been treated with at least 2 therapies, will be treated with their own white blood cells that are genetically transduced.metastasized melanomagemetastaseerde huidkankerNL-OMON28054KI-AV25
进行中（未招募）
1 期
Study of everolimus treatment in newly-diagnosed patients with advanced GI neuroendocrine tumorsWell or moderately differentiated advanced (metastatic or unresectable) GI or pancreatic neuroendocrine tumors.MedDRA version: 14.1Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006160-48-GRHellenic Cooperative Oncology Group29
进行中（未招募）
1 期
Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapyEUCTR2015-005504-28-NLEuropean Organisation for Research and Treatment of Cancer80
进行中（未招募）
1 期
Study of immunotherapy for treatment of patients with malignancies of the thymus (type B3 thymoma and thymic carcinoma) and already treated with chemotherapyEUCTR2015-005504-28-GBEuropean Organisation for Research and Treatment of Cancer80